scholarly journals Intravascular ultrasound-guided interventions in coronary artery disease: a systematic literature review, with decision-analytic modelling, of outcomes and cost-effectiveness.

2000 ◽  
Vol 4 (35) ◽  
Author(s):  
Berry ◽  
Kelly ◽  
Hutton ◽  
Lindsay ◽  
Blaxill ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Literature Review ◽  
Intravascular Ultrasound ◽  
Systematic Literature Review ◽  
Ultrasound Guided ◽  
Decision Analytic Modelling ◽  
Artery Disease

scholarly journals A Systematic Literature Review of Three Stenting Strategies for Bifurcation Lesions in Coronary Artery Disease

10.36469/9746 ◽  
2019 ◽  
Vol 6 (2) ◽  
pp. 96-105
Author(s):  
Larragem Parsley-Raines ◽  
Dominique M. Brandt ◽  
Dillon L. Carr ◽  
Sabrina Uhry ◽  
Stephanie A. Donauer ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Literature Review ◽  
Systematic Literature Review ◽  
Side Branch ◽  
Cochrane Library ◽  
Significant Heterogeneity ◽  
Target Vessel ◽  
Bifurcation Lesions ◽  
Artery Disease

Background: Bifurcation lesions represent 15-20% of all patients undergoing a percutaneous coronary intervention (PCI) for coronary artery disease. The provisional 1-stent stenting strategy is the preferred strategy to treat bifurcation lesions. Other strategies used to treat bifurcation lesions include 2-stent complex stenting strategies and the Tryton Side Branch Stent® (TSB)—a dedicated side-branch stent for bifurcation lesions, which gained FDA approval in March 2017. Objectives: To conduct a systematic literature review of the safety and effectiveness of three stenting strategies (provisional, complex, and Tryton Side Branch Stent®) for bifurcation lesions with a side-branch diameter ≥2.25 mm, undergoing PCI. Methods: Literature searches in Medline, Cochrane Library, Web of Science and Embase were conducted to identify prospective clinical trials from January 2007-July 2017. Results: 602 articles were identified. Nine articles (6275 patients) met all inclusion criteria. Seven studies (5282 patients) compared provisional to complex stenting strategies. Two studies (993 patients) compared provisional to the TSB. Outcomes of interest reported were target vessel failure in 2 studies, major adverse cardiac event (MACE) (cardiac death, all myocardial infarction, ischemic driven target legion revascularization TLR) in 5 studies. For target vessel failure, the provisional strategy ranged from 5.6% to 15.6 %; complex at 7.2% (one study); and TSB from 11.3% to 17.4%. For MACE, provisional strategy ranged from 8%-13.2%; complex from 11.9%-15.2%; and TSB from 8.2%-18.6%. Conclusions: To our knowledge, this is the first review comparing three bifurcation lesion stenting strategies. Significant heterogeneity in the study design of the nine studies reviewed prevented a meta-analysis. A clinical trial comparing the TSB to both the provisional and complex strategies would provide better inference on the safety and effectiveness when comparing strategies.

scholarly journals Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease

2005 ◽  
Vol 45 (2) ◽  
pp. 204-211 ◽  
Author(s):  
Amir-Ali Fassa ◽  
Kenji Wagatsuma ◽  
Stuart T. Higano ◽  
Verghese Mathew ◽  
Gregory W. Barsness ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Intravascular Ultrasound ◽  
Left Main Coronary Artery ◽  
Ultrasound Guided ◽  
Left Main ◽  
Main Coronary Artery Disease ◽  
Artery Disease

Clinical Outcomes of Bioresorbable Scaffold in Coronary Artery Disease: A Systematic Literature Review

2016 ◽  
Vol 29 (1) ◽  
pp. 57-69 ◽  
Author(s):  
Yann Shan Keh ◽  
Jonathan Yap ◽  
Khung Keong Yeo ◽  
Tian Hai Koh ◽  
Eric Eeckhout
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Literature Review ◽  
Clinical Outcomes ◽  
Systematic Literature Review ◽  
Bioresorbable Scaffold ◽  
Artery Disease

scholarly journals Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e044054
Author(s):  
Victoria McCreanor ◽  
Alexandra Nowbar ◽  
Christopher Rajkumar ◽  
Adrian G Barnett ◽  
Darrel Francis ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Coronary Intervention ◽  
Single Vessel ◽  
Vessel Coronary Artery Disease ◽  
Effectiveness Analysis ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
Vessel Coronary Artery

ObjectiveTo evaluate the cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina despite anti-anginal therapy.DesignA cost-effectiveness analysis comparing PCI with placebo. A Markov model was used to measure incremental cost-effectiveness, in cost per quality-adjusted life-years (QALYs) gained, over 12 months. Health utility weights were estimated using responses to the EuroQol 5-level questionnaire, from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial and UK preference weights. Costs of procedures and follow-up consultations were derived from Healthcare Resource Group reference costs and drug costs from the National Health Service (NHS) drug tariff. Probabilistic sensitivity analysis was undertaken to test the robustness of results to parameter uncertainty. Scenario analyses were performed to test the effect on results of reduced pharmaceutical costs in patients undergoing PCI, and the effect of patients crossing over from placebo to PCI due to refractory angina within 12 months.SettingFive UK NHS hospitals.Participants200 adult patients with stable angina and angiographically severe single-vessel coronary artery disease on anti-anginal therapy.InterventionsAt recruitment, patients received 6 weeks of optimisation of medical therapy for angina after which they were randomised to PCI or a placebo procedure.Outcome measuresIncremental cost-effectiveness ratio (ICER) expressed as cost (in £) per QALY gained for PCI compared with placebo.ResultsThe estimated ICER is £90 218/QALY gained when using PCI compared with placebo in patients receiving medical treatment for angina due to single-vessel coronary artery disease. Results were robust under sensitivity analyses.ConclusionsThe ICER for PCI compared with placebo, in patients with single-vessel coronary artery disease and angina on anti-anginal medication, exceeds the threshold of £30 000 used by the National Institute of Health and Care Excellence when undertaking health technology assessment for the NHS context.Trial registration: The ORBITA study is registered with ClinicalTrials.gov, number NCT02062593.

Sign in / Sign up

Export Citation Format

Share Document